FXS5626 for Non-Infectious Eye Inflammation
Part of Eyes & vision clinical trials.
This trial tests a new drug called FXS5626 to treat non-infectious uveitis—inflammation inside the eye that doesn't come from infection. The study looks at whether this drug can reduce eye inflammation and improve vision in people whose condition isn't controlled with steroid eye drops and oral steroids alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 and able to understand and follow study procedures
- BMI between 18–30 kg/m² (weight at least 50 kg for men, 45 kg for women)
- Diagnosis of non-infectious uveitis (inflammation in the middle, back, or all layers of the eye) that is actively present despite steroid treatment
- Currently taking oral prednisone (10–60 mg per day) or equivalent steroid for at least 2 weeks
- Willing to use effective contraception and not plan pregnancy or donate sperm/eggs for 1 month after treatment ends
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests baricitinib (a medication that calms a specific immune pathway) for people with non-infectious uveitis that has not improved with prior biologic treatments. It also looks at side effects and how well vision and eye inflammation respond when other medicines are stopped before starting the study drug.
This study tests a new drug (GenSci048) for people with active, non-infectious uveitis in the middle or back of the eye, who are already taking oral steroids. The goal is to see if the drug can better control inflammation and reduce the need for steroids.
This trial tests a combination of two medications (adalimumab and mycophenolate mofetil) to reduce eye inflammation in people with uveitis that requires steroids. It aims to help patients use less steroid medication while keeping their uveitis under control.
This trial tests a new cell therapy called TRX103 for people with active uveitis not caused by an infection. It aims to see if the treatment is safe and helps reduce eye inflammation.
This trial tests a new eye drop (tacrolimus) to treat non-infectious anterior uveitis, an inflammation in the front part of the eye. It may help reduce the need for steroid eye drops.
This study follows adults with non-infectious uveitis (intermediate, posterior, or pan-uveitis) to better understand inflammation activity and treatment needs. It also follows adults having planned eye surgery (like cataract or vitreoretinal surgery) to compare groups.
Hear when a new Active Non-anterior, Non-infectious Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.